- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Flu Shot During Pregnancy; Liquid Biopsy for NSCLC; Physician-Generated Revenue
Researchers have confirmed that there is no link between flu shots and miscarriages; a liquid biopsy is as effective as tissue-based testing for identifying treatment for lung cancer; and physicians generate an average of $2 million a year for hospitals.
No Link Between Flu Shot, Miscarriage
Researchers who previously raised questions about the safety of getting a flu shot during pregnancy have announced data from their most recent study showing that there is no link between the vaccine and miscarriage. According to STAT News, the current study was bigger than the first and looked specifically at this link. The study will be submitted to a peer-reviewed journal for publication.
Liquid Biopsy for Lung Cancer Treatment
The liquid biopsy test Guardant360 is as effective as standard-of-care tissue genotyping tests for detecting biomarkers and thus guiding treatment for patients with metastatic non-small cell lung cancer, according to a press release from the American Association for Cancer Research. The test, which also has quicker turn-around time than the standard of care, can identify 1 prognostic and 7 predictive biomarkers in the blood.
Physicians Bring in $2 Million a Year for Hospitals
A survey from Merritt Hawkins revealed that physicians are major drivers of revenue for hospitals, generating an average of $2,378,727 per year in net revenue for their affiliated hospital. Cardiovascular surgeons landed the top spot on the list, generating an average of nearly $3.7 million a year, followed by invasive cardiologists at $3.5 million, neurosurgeons at $3.4 million, and orthopedic surgeons at $3.3 million.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
